W.H.O. Partner Program Allocates 238,000 Doses of Mpox Vaccine to Four Countries Medical Countermeasures March 19, 2025 …
Emergent BioSolutions Secures $27 Million in International Orders for Critical Medical Countermeasures Medical Countermeasures March 18, 2025 …
GigaGen Wins BARDA Contract to Develop Biothreat Countermeasures Medical Countermeasures October 3, 2024 …
Acurx Announces Anthrax Susceptibility to ACX-375 Analogues Medical Countermeasures September 26, 2024 …
Disappointing Results for Tecovirimat Mpox Trial in the DRC Medical Countermeasures August 15, 2024 …
Lassa Fever Vaccine Study Supports Advancement to Phase I Trial Medical Countermeasures August 14, 2024 …
Are We There Yet? Agent Agnostic Metagenome Sequencing for Biothreat Detection Biodetection July 31, 2024 …
Maxwell Biosciences Enters CRADA with USAMRIID to Test Potential Therapeutics Industry News May 8, 2024 …
Antiviral for Sudan Ebolavirus; Ebola Pathogenicity in Pigs; Repurposing SARS-CoV-2 Drugs for Marburg Pathogens April 3, 2024 …
Study on Ebola Vaccines and Boosting Regimen Contributes to Future Outbreak Preparedness Medical Countermeasures April 3, 2024 …
BARDA Offers Preclinical Testing Assistance for Botulinum Neurotoxin Candidate Therapeutics Medical Countermeasures February 9, 2024 …
A Clear Picture of Poxvirus Cores Could Help Build Better Countermeasures Research February 5, 2024 …
First Light Diagnostics Receives FDA Clearance for Rapid Anthrax Test Biodetection December 5, 2023 …
NanoViricides’ Phase 1 Broad-Spectrum Antiviral Highly Effective for Mpox and Smallpox Medical Countermeasures November 14, 2023 …
Molecular Diagnostic Test for Six Biothreat Pathogens Receives FDA Clearance Biodetection September 19, 2023 …
